Exchange: NASDAQ·Updated 07:30 PM EST

PHAR News

News
all
press releases
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Stock Has Average Price Target of $39.67 According to Analysts
Shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) have been given an average recommendation of "Moderate Buy" by the five brokerages that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and three have ass...
MarketBeat
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Stock Has Average Price Target of $39.67 According to Analysts
Shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) have been given an average recommendation of "Moderate Buy" by the five brokerages that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and three have ass...
MarketBeat
More News
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) was the target of a large increase in short interest in the month of October. As of October 30th, there was short interest totaling 25,783 shares, an increase of 92.0% from the October 15th total of 13,429 shares. Based on an average...
MarketBeat
Pharming (NASDAQ:PHAR) reported third-quarter financial results on Tuesday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. Forread more...
Benzinga
(RTTNews) - On Wednesday, Pharming Group N.V. (PHAR) announced positive topline results from a Phase II study evaluating Leniolisib in patients with genetically identifiable primary immunodeficiencies (PIDs) associated with immune dysregulation linked to altered PI3Kdelta signa...
Nasdaq News: Markets
JNJ reports third-quarter results on Tuesday, and Koyfin analysts expect modest revenue growth and lower earnings.
Stocktwits
(RTTNews) - Pharming Group N.V. (PHARM.AS) said the U.S. Food and Drug Administration has approved Joenja (leniolisib) for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome, or APDS, who weigh at least 27 kg...
Nasdaq News: Markets
Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky PR Newswire NEW YORK, Aug. 7, 2026 Pharming Group told investors to expect up to $425 million in 2026 revenue. The Company now expects as little as $375...
PR Newswire
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Pharming Group N.V. (Pharming or the Company) (NASDAQ: PHAR) investors concerning the Companys possible violations of the federal securities laws...
Business Wire
Law Offices of Howard G. Smith announces an investigation on behalf of Pharming Group N.V. (Pharming or the Company) (NASDAQ: PHAR) investors concerning the Companys possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN PHARMING GROUP N.V. (PHAR), CONTACT THE...
Business Wire
The Law Offices of Frank R. Cruz announces an investigation of Pharming Group N.V. (Pharming or the Company) (NASDAQ: PHAR) on behalf of investors concerning the Companys possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON PHARMING GROUP N.V. (PHAR), CLICK HERE...
Business Wire

Advertisement|Remove ads.